200,000+ products from a single source!

sales@angenechem.com

Home > Amines > 135062-02-1

135062-02-1

135062-02-1 | (S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid

CAS No: 135062-02-1 Catalog No: AG0038AM MDL No:MFCD00906179

Product Description

Catalog Number:
AG0038AM
Chemical Name:
(S)-2-Ethoxy-4-[2-[[3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl]amino]-2-oxoethyl]benzoic acid
CAS Number:
135062-02-1
Molecular Formula:
C27H36N2O4
Molecular Weight:
452.5857
MDL Number:
MFCD00906179
IUPAC Name:
2-ethoxy-4-[2-[[(1S)-3-methyl-1-(2-piperidin-1-ylphenyl)butyl]amino]-2-oxoethyl]benzoic acid
InChI:
InChI=1S/C27H36N2O4/c1-4-33-25-17-20(12-13-22(25)27(31)32)18-26(30)28-23(16-19(2)3)21-10-6-7-11-24(21)29-14-8-5-9-15-29/h6-7,10-13,17,19,23H,4-5,8-9,14-16,18H2,1-3H3,(H,28,30)(H,31,32)/t23-/m0/s1
InChI Key:
FAEKWTJYAYMJKF-QHCPKHFHSA-N
SMILES:
CCOc1cc(ccc1C(=O)O)CC(=O)N[C@H](c1ccccc1N1CCCCC1)CC(C)C
UNII:
668Z8C33LU
NSC Number:
759893

Properties

Complexity:
619  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
452.268g/mol
Formal Charge:
0
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
5  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
452.595g/mol
Monoisotopic Mass:
452.268g/mol
Rotatable Bond Count:
10  
Topological Polar Surface Area:
78.9A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.2  

Literature

Title Journal
Toxicological evaluation of acyl glucuronides utilizing half-lives, peptide adducts, and immunostimulation assays. Toxicology in vitro : an international journal published in association with BIBRA 20151225
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chemical research in toxicology 20150518
Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicological sciences : an official journal of the Society of Toxicology 20131201
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology 20131101
The influence of oral antidiabetic drugs on cellular drug uptake mediated by hepatic OATP family members. Basic & clinical pharmacology & toxicology 20130401
In vitro and in vivo studies on a novel solid dispersion of repaglinide using polyvinylpyrrolidone as the carrier. Drug development and industrial pharmacy 20121101
Validated stability-indicating spectrofluorimetric method with enhanced sensitivity for determination of repaglinide in tablets. Journal of fluorescence 20121101
Strict glycaemic control improves skin microcirculation in patients with type 2 diabetes: a report from the Diabetes mellitus And Diastolic Dysfunction (DADD) study. Diabetes & vascular disease research 20121001
NeuroD1 A45T and PAX4 R121W polymorphisms are associated with plasma glucose level of repaglinide monotherapy in Chinese patients with type 2 diabetes. British journal of clinical pharmacology 20120901
Analysis of repaglinide enantiomers in pharmaceutical formulations by capillary electrophoresis using 2,6-di-o-methyl-β-cyclodextrin as a chiral selector. Journal of chromatographic science 20120901
Use of mechanistic modeling to assess interindividual variability and interspecies differences in active uptake in human and rat hepatocytes. Drug metabolism and disposition: the biological fate of chemicals 20120901
Utility of drug depletion-time profiles in isolated hepatocytes for accessing hepatic uptake clearance: identifying rate-limiting steps and role of passive processes. Drug metabolism and disposition: the biological fate of chemicals 20120801
A comprehensive assessment of repaglinide metabolic pathways: impact of choice of in vitro system and relative enzyme contribution to in vitro clearance. Drug metabolism and disposition: the biological fate of chemicals 20120701
Synthesis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors. European journal of medicinal chemistry 20120701
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry 20120524
Association of muscarinic M₃ receptors and Kir6.1 with caveolae in human detrusor muscle. European journal of pharmacology 20120515
Discrepancies among consensus documents, guidelines, clinical practice and the legal framework for the treatment of type 2 diabetes mellitus patients. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514
Adulteration of herbal antidiabetic products with undeclared pharmaceuticals: a case series in Hong Kong. British journal of clinical pharmacology 20120501
Influence of atorvastatin on the pharmacodynamic and pharmacokinetic activity of repaglinide in rats and rabbits. Molecular and cellular biochemistry 20120501
Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data. Drug metabolism and disposition: the biological fate of chemicals 20120501
KCNQ1 gene polymorphisms are associated with the therapeutic efficacy of repaglinide in Chinese type 2 diabetic patients. Clinical and experimental pharmacology & physiology 20120501
Gemfibrozil is a strong inactivator of CYP2C8 in very small multiple doses. Clinical pharmacology and therapeutics 20120501
[Hypoglycemia - frequency, causes, induced costs]. Deutsche medizinische Wochenschrift (1946) 20120501
The pharmacokinetics and hepatic disposition of repaglinide in pigs: mechanistic modeling of metabolism and transport. Molecular pharmaceutics 20120402
Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model. The Journal of pharmacology and experimental therapeutics 20120401
Importance of the Kir6.2 N-terminus for the interaction of glibenclamide and repaglinide with the pancreatic K(ATP) channel. Naunyn-Schmiedeberg's archives of pharmacology 20120301
Role of the amino-terminal transmembrane domain of sulfonylurea receptor SUR2B for coupling to K(IR)6.2, ligand binding, and oligomerization. Naunyn-Schmiedeberg's archives of pharmacology 20120301
In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions. Pharmaceutical research 20120201
Variations in tissue selectivity amongst insulin secretagogues: a systematic review. Diabetes, obesity & metabolism 20120201
Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine. Journal of pharmacokinetics and pharmacodynamics 20120201
Association of a SLC30A8 genetic variant with monotherapy of repaglinide and rosiglitazone effect in newly diagnosed type 2 diabetes patients in China. Biomedical and environmental sciences : BES 20120201
Repaglinide: a review of its use in type 2 diabetes mellitus. Drugs 20120122
Design and optimization of a stomach-specific drug delivery system of repaglinide: application of simplex lattice design. Pharmaceutical development and technology 20120101
From evidence assessments to coverage decisions?: the case example of glinides in Germany. Health policy (Amsterdam, Netherlands) 20120101
Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery. Journal of drug delivery 20120101
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulation. Journal of clinical pharmacology 20120101
Platelet hyperaggregability in high-fat fed rats: a role for intraplatelet reactive-oxygen species production. Cardiovascular diabetology 20120101
Cellular dysfunction in diabetes as maladaptive response to mitochondrial oxidative stress. Experimental diabetes research 20120101
In vitro and in vivo evaluation of ordered mesoporous silica as a novel adsorbent in liquisolid formulation. International journal of nanomedicine 20120101
Editorial preface to the first issue of 2012. Journal of cardiovascular disease research 20120101
Athero-protective actions of two oral antidiabetic drugs: Suppression of inflammation and oxidative stress. Journal of cardiovascular disease research 20120101
Evaluation of the effects of glimepiride (Amaryl) and repaglinide (novoNorm) on atherosclerosis progression in high cholesterol-fed male rabbits. Journal of cardiovascular disease research 20120101
Chronic kidney disease, severe arterial and arteriolar sclerosis and kidney neoplasia: on the spectrum of kidney involvement in MELAS syndrome. BMC nephrology 20120101
Effect of genetic polymorphism of UCP2-866 G/A on repaglinide response in Chinese patients with type 2 diabetes. Die Pharmazie 20120101
The Influence of MDR1 G2677T/a genetic polymorphisms on the pharmacokinetics of repaglinide in healthy Chinese volunteers. Pharmacology 20120101
Preparation, characterization and in vivo evaluation of antihyperglycemic activity of microwave generated repaglinide solid dispersion. Chemical & pharmaceutical bulletin 20120101
Oxidative/nitrosative stress and protein damages in aqueous humor of hyperglycemic rabbits: effects of two oral antidiabetics, pioglitazone and repaglinide. Experimental diabetes research 20120101
Performance scores in general practice: a comparison between the clinical versus medication-based approach to identify target populations. PloS one 20120101
Uncovering undetected hypoglycemic events. Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
[Prevalence of diabetes mellitus in geriatric patients in nursing homes of Cádiz. Diagerca study]. Revista espanola de geriatria y gerontologia 20120101
Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. ISRN endocrinology 20120101
Pharmacological approaches to the management of type 2 diabetes in fasting adults during Ramadan. Diabetes, metabolic syndrome and obesity : targets and therapy 20120101
Antidiabetic drugs and kidney disease--recommendations of the Swiss Society for Endocrinology and Diabetology. Swiss medical weekly 20120101
Randomized study of repaglinide alone and in combination with metformin in Chinese subjects with type 2 diabetes naive to oral antidiabetes therapy. Expert opinion on pharmacotherapy 20111201
Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review. Clinical therapeutics 20111201
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology 20111201
Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. Diabetes research and clinical practice 20111101
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. International journal of clinical practice 20111101
Hypoglycemia revisited in the acute care setting. Yonsei medical journal 20111101
Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs). European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20111009
Kinetic characterization of rat hepatic uptake of 16 actively transported drugs. Drug metabolism and disposition: the biological fate of chemicals 20111001
Dose-dependent interaction between gemfibrozil and repaglinide in humans: strong inhibition of CYP2C8 with subtherapeutic gemfibrozil doses. Drug metabolism and disposition: the biological fate of chemicals 20111001
Effect of nicotinamide mononucleotide on insulin secretion and gene expressions of PDX-1 and FoxO1 in RIN-m5f cells. Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20111001
The Effects of Glyburide on Apoptosis and Endoplasmic Reticulum Stress in INS-1 Cells in a Glucolipotoxic Condition. Diabetes & metabolism journal 20111001
Glitazone-like action of glimepiride and glibenclamide in primary human adipocytes. Diabetes, obesity & metabolism 20110901
Meal-induced increases in C-reactive protein, interleukin-6 and tumour necrosis factor α are attenuated by prandial + basal insulin in patients with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 20110901
Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug metabolism and disposition: the biological fate of chemicals 20110901
The pregnane X receptor agonist St John's Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide. Clinical pharmacokinetics 20110901
Enhanced glycemic control with combination therapy for type 2 diabetes in primary care. Diabetes therapy : research, treatment and education of diabetes and related disorders 20110901
Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. European heart journal 20110801
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus. Clinical and experimental pharmacology & physiology 20110801
Lipid nanocarriers (GeluPearl) containing amphiphilic lipid Gelucire 50/13 as a novel stabilizer: fabrication, characterization and evaluation for oral drug delivery. Nanotechnology 20110708
Expression of sulfonylurea receptors in rat taste buds. Acta histochemica 20110701
Effects of SLCO1B1 polymorphisms on the pharmacokinetics and pharmacodynamics of repaglinide in healthy Chinese volunteers. European journal of clinical pharmacology 20110701
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation. Journal of pharmaceutical sciences 20110601
In vivo and cytotoxicity evaluation of repaglinide-loaded binary solid lipid nanoparticles after oral administration to rats. Journal of pharmaceutical sciences 20110601
Hydrogels based on interpenetrating network of chitosan and polyvinyl pyrrolidone for pH-sensitive delivery of repaglinide. Current drug discovery technologies 20110601
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes care 20110601
Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy. Annales d'endocrinologie 20110601
Primary language, income and the intensification of anti-glycemic medications in managed care: the (TRIAD) study. Journal of general internal medicine 20110501
A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes, obesity & metabolism 20110501
Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide. Drug metabolism and disposition: the biological fate of chemicals 20110501
[Clinical parameters for molecular testing of Maturity Onset Diabetes of the Young (MODY)]. Deutsche medizinische Wochenschrift (1946) 20110501
Simultaneous identification and validated quantification of 11 oral hypoglycaemic drugs in plasma by electrospray ionisation liquid chromatography-mass spectrometry. Analytical and bioanalytical chemistry 20110401
Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clinical pharmacology and therapeutics 20110401
Diabetes treatment and cardiovascular safety. Diabetes care 20110401
Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes care 20110401
A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. Journal of medicinal chemistry 20110324
Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. European journal of endocrinology 20110301
Effects of KCNQ1 polymorphisms on the therapeutic efficacy of oral antidiabetic drugs in Chinese patients with type 2 diabetes. Clinical pharmacology and therapeutics 20110301
Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20110201
Validated spectrophotometric methods for determination of some oral hypoglycemic drugs. Drug discoveries & therapeutics 20110201
Aqueous Extract from Hibiscus sabdariffa Linnaeus Ameliorate Diabetic Nephropathy via Regulating Oxidative Status and Akt/Bad/14-3-3γ in an Experimental Animal Model. Evidence-based complementary and alternative medicine : eCAM 20110101
Small molecule inhibitors of the human papillomavirus E1-E2 interaction. Current topics in microbiology and immunology 20110101
Navigating the human metabolome for biomarker identification and design of pharmaceutical molecules. Journal of biomedicine & biotechnology 20110101
Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. Diabetes technology & therapeutics 20110101
Understanding diabetes in patients with HIV/AIDS. Diabetology & metabolic syndrome 20110101
Temporal trends in the initiation of glucose-lowering medications after a first-time myocardial infarction - a nationwide study between 1997 and 2006. Cardiovascular diabetology 20110101
Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. Current drug metabolism 20110101
Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in. Chinese medical journal 20110101
2-Deoxy-D-glucose reverses the Indian red scorpion venom-induced cardiopulmonary abnormalities in anesthetized rats. Indian journal of experimental biology 20110101
Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress. Biologics : targets & therapy 20110101
Carotid intima-media thickness as a surrogate marker of cardiovascular disease in diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Hypersensitivity to repaglinide. Journal of investigational allergology & clinical immunology 20110101
Multiple thromboembolism with multiple causes in a 69-year-old woman: a case report. Journal of medical case reports 20110101
Precursor B-cell acute lymphoblastic leukemia presenting as obstructive jaundice: a case report. Journal of medical case reports 20110101
Diabetes and Ramadan: an update on use of glycemic therapies during fasting. Annals of Saudi medicine 20110101
Extensive Spinal Cord Injury following Staphylococcus aureus Septicemia and Meningitis. Case reports in neurology 20110101
New onset diabetes after transplantation (NODAT): an overview. Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
Small molecule inhibitors of human papillomavirus protein - protein interactions. The open virology journal 20110101
Cancer risk in type 2 diabetes mellitus: metabolic links and therapeutic considerations. Journal of nutrition and metabolism 20110101
Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PloS one 20110101
A review of methods used in assessing non-serious adverse drug events in observational studies among type 2 diabetes mellitus patients. Health and quality of life outcomes 20110101
Medicinal chemistry of novel anti-diabetic drugs. The open medicinal chemistry journal 20110101
South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome. Indian journal of endocrinology and metabolism 20110101
Ramadan and diabetes: As-Saum (The fasting). Indian journal of endocrinology and metabolism 20110101
[Genetic polymorphisms of SLCO1B1 for drug pharmacokinetics and its clinical implications]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20110101
Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open medicine : a peer-reviewed, independent, open-access journal 20110101
Novel anti-inflammatory effects of repaglinide in rodent models of inflammation. Pharmacology 20110101
Acute toxicity study of tilmicosin-loaded hydrogenated castor oil-solid lipid nanoparticles. Particle and fibre toxicology 20110101
Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. Diabetology & metabolic syndrome 20110101
Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes, metabolic syndrome and obesity : targets and therapy 20110101
In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors. International journal of molecular sciences 20110101
Delusional infestation in a patient with renal failure, metabolic syndrome, and chronic cerebrovascular disease treated with aripiprazole: a case report. Case reports in medicine 20110101
Multiple myeloma and diabetes. ISRN endocrinology 20110101
Separation and quantification of eight antidiabetic drugs on a high-performance liquid chromatography: its application to human plasma assay. ISRN pharmaceutics 20110101
Formulation and evaluation of transdermal patch of repaglinide. ISRN pharmaceutics 20110101
Carbamazepine-induced acute generalized exanthematous pustulosis: a case report. The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20110101
Angelica archengelica extract induced perturbation of rat skin and tight junctional protein (ZO-1) of HaCaT cells. Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences 20110101
Updated review: improved glycemic control with repaglinide-metformin in fixed combination for patients with type 2 diabetes. Clinical medicine insights. Endocrinology and diabetes 20110101
Fewer major amputations among individuals with diabetes in Finland in 1997-2007: a population-based study. Diabetes care 20101201
Association analysis of SLC30A8 rs13266634 and rs16889462 polymorphisms with type 2 diabetes mellitus and repaglinide response in Chinese patients. European journal of clinical pharmacology 20101201
Smoking and risk for diabetes incidence and mortality in Korean men and women. Diabetes care 20101201
Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes care 20101201
Electrochemical characterization of repaglinide and its determination in human plasma using liquid chromatography with dual-channel coulometric detection. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20101201
Exercise and type 2 diabetes: the American College of Sports Medicine and the American Diabetes Association: joint position statement. Diabetes care 20101201
Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes care 20101201
Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism. British journal of clinical pharmacology 20101201
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes therapy : research, treatment and education of diabetes and related disorders 20101201
Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes care 20101101
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. Bioorganic & medicinal chemistry letters 20101101
SLCO1B1 polymorphism and oral antidiabetic drugs. Basic & clinical pharmacology & toxicology 20101001
[Electrocardiographic score: application in exercise test for the assessment of ischemic preconditioning]. Arquivos brasileiros de cardiologia 20101001
Organic solvent-free approach to single step fabrication of Eudragit nanoparticles using Labrasol. Die Pharmazie 20101001
Sitagliptin-induced hemolysis. Indian journal of pharmacology 20101001
[Sulfonylureas dosage: from therapeutic monitoring to differential diagnosis of hyperinsulinism]. Revue medicale de Liege 20100901
In vitro characterization and invivo toxicity study of repaglinide loaded poly (methyl methacrylate) nanoparticles. International journal of pharmaceutics 20100830
The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes care 20100801
Recommendations for management of diabetes during Ramadan: update 2010. Diabetes care 20100801
Effect of lipid matrix on repaglinide-loaded solid lipid nanoparticles for oral delivery. Therapeutic delivery 20100701
Prevalence and correlates of inadequate glycaemic control: results from a nationwide survey in 6,671 adults with diabetes in Brazil. Acta diabetologica 20100601
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. International journal of clinical practice 20100601
Neuropathy, retinopathy, and glucose-lowering treatments. Diabetes care 20100601
IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population. Acta pharmacologica Sinica 20100601
Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. Journal of clinical pharmacology 20100501
The nasty surprise of a complex drug-drug interaction. Drug discovery today 20100501
Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. Diabetes research and clinical practice 20100401
Coping with changes in the Defined Daily Dose in a longitudinal drug consumption database. Pharmacy world & science : PWS 20100401
Symptomatic hypoglycemia associated with trimethoprim/sulfamethoxazole and repaglinide in a diabetic patient. The Annals of pharmacotherapy 20100401
Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Annals of the rheumatic diseases 20100401
A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta pharmacologica Sinica 20100401
KCNJ11 Lys23Glu and TCF7L2 rs290487(C/T) polymorphisms affect therapeutic efficacy of repaglinide in Chinese patients with type 2 diabetes. Clinical pharmacology and therapeutics 20100301
Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin. Journal of Korean medical science 20100301
Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. Archives of pharmacal research 20100301
Opening of ATP-sensitive potassium channel by insulin in the brain-induced insulin secretion in Wistar rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20100201
Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. Journal of clinical pharmacology 20100201
Diabetes under control: Understanding oral antidiabetic agents. The American journal of nursing 20100201
Population pharmacokinetic modelling of repaglinide in healthy volunteers by using Non-Parametric Adaptive Grid Algorithm. Journal of clinical pharmacy and therapeutics 20100201
Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits. Bioscience trends 20100201
Aspects of insulin treatment. Diabetes care 20100101
Development of repaglinide loaded solid lipid nanocarrier: selection of fabrication method. Current drug delivery 20100101
Effect of meglitinides on postprandial ghrelin secretion pattern in type 2 diabetes mellitus. Diabetes technology & therapeutics 20100101
Anti-hyperglycemic and anti-hyperlipidemic effects of guava leaf extract. Nutrition & metabolism 20100101
Effects of lifestyle measures, antiobesity agents, and bariatric surgery on serological markers of inflammation in obese patients. Mediators of inflammation 20100101
Statins, antihypertensive treatment, and blood pressure control in clinic and over 24 hours: evidence from PHYLLIS randomised double blind trial. BMJ (Clinical research ed.) 20100101
Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vascular health and risk management 20100101
Development of a cell-based high-throughput assay to screen for inhibitors of organic anion transporting polypeptides 1B1 and 1B3. Current chemical genomics 20100101
Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ (Clinical research ed.) 20100101
CYP3A4 genetic polymorphism influences repaglinide's pharmacokinetics. Pharmacology 20100101
Algorithm for the treatment of type 2 diabetes: a position statement of Brazilian Diabetes Society. Diabetology & metabolic syndrome 20100101
Increased postprandial nonesterified fatty acid appearance and oxidation in type 2 diabetes is not fully established in offspring of diabetic subjects. PloS one 20100101
The well-being and treatment satisfaction of diabetic patients in primary care. Health and quality of life outcomes 20100101
The tsim tsoum approaches for prevention of cardiovascular disease. Cardiology research and practice 20100101
Association of hypoglycemic symptoms with patients' rating of their health-related quality of life state: a cross sectional study. Health and quality of life outcomes 20100101
Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors. Cardiovascular diabetology 20100101
Development of Spectrofluorimetric and HPLC Methods for In vitro Analysis of Repaglinide. Indian journal of pharmaceutical sciences 20100101
Characteristics of coronary artery disease in symptomatic type 2 diabetic patients: evaluation with CT angiography. Cardiovascular diabetology 20100101
Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutrition & metabolism 20100101
Carbamazepine-loaded porous microspheres for short-term sustained drug delivery. Journal of young pharmacists : JYP 20100101
In vitro Evaluation of Novel Sustained Release Microspheres of Glipizide Prepared by the Emulsion Solvent Diffusion-Evaporation Method. Journal of young pharmacists : JYP 20100101
Repaglinide/metformin fixed-dose combination to improve glycemic control in patients with type 2 diabetes: an update. Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy 20100101
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open medicine : a peer-reviewed, independent, open-access journal 20100101
Design and optimization of floating drug delivery system of acyclovir. Indian journal of pharmaceutical sciences 20100101
Nateglinide versus repaglinide for type 2 diabetes mellitus in China. Acta diabetologica 20091201
Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans. Diabetes care 20091201
CYP2C8 activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe. Drug metabolism and disposition: the biological fate of chemicals 20091201
Practical guidance on intensification of insulin therapy with BIAsp 30: a consensus statement. International journal of clinical practice 20091101
Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines. Diabetes care 20091101
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes care 20091101
Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 20091101
Twice-daily and three-times-daily dosing of a repaglinide/metformin fixed-dose combination tablet provide similar glycaemic control. Diabetes, obesity & metabolism 20091001
Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 20091001
Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes care 20091001
Accuracy of Veterans Affairs databases for diagnoses of chronic diseases. Preventing chronic disease 20091001
Impact of OATP transporters on pharmacokinetics. British journal of pharmacology 20091001
Twice-daily dosing of a repaglinide/metformin fixed-dose combination tablet provides glycaemic control comparable to rosiglitazone/metformin tablet. Diabetes, obesity & metabolism 20090901
The role of transporters in the pharmacokinetics of orally administered drugs. Pharmaceutical research 20090901
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 20090901
Global variation in CYP2C8-CYP2C9 functional haplotypes. The pharmacogenomics journal 20090801
Thiazolidinediones and cardiovascular risk - a question of balance. Current cardiology reviews 20090801
Change in glucometer settings as a cause of sudden deterioration of glycemic control in type 2 diabetes. Diabetes technology & therapeutics 20090701
Successful treatment of repaglinide-induced hypoglycemia with octreotide. The American journal of emergency medicine 20090701
Metformin/Repaglinide (PrandiMet) for type 2 diabetes. The Medical letter on drugs and therapeutics 20090601
Modulation of nitrosative/oxidative stress in the lung of hyperglycemic rabbits by two antidiabetics, pioglitazone and repaglinide. Experimental lung research 20090601
Determination of antihyperglycemic drugs in nanomolar concentration levels by micellar electrokinetic chromatography with non-ionic surfactant. Journal of chromatography. A 20090515
Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paulo, Brazil) 20090501
Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2. Journal of medicinal chemistry 20090409
Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. Journal of proteome research 20090401
Analysis of two KCNJ11 neonatal diabetes mutations, V59G and V59A, and the analogous KCNJ8 I60G substitution: differences between the channel subtypes formed with SUR1. The Journal of biological chemistry 20090313
Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. Acta diabetologica 20090301
Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta diabetologica 20090301
Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial. Current medical research and opinion 20090301
Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus. Journal of diabetes 20090301
Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes care 20090101
Standards of medical care in diabetes--2009. Diabetes care 20090101
The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. Journal of endocrinological investigation 20090101
Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovascular diabetology 20090101
Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide. Drug safety 20090101
DreamTel; Diabetes risk evaluation and management tele-monitoring study protocol. BMC endocrine disorders 20090101
Indices of insulin sensitivity and secretion from a standard liquid meal test in subjects with type 2 diabetes, impaired or normal fasting glucose. Nutrition journal 20090101
Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharmaceutical development and technology 20090101
Acute heart failure in a patient with metabolic syndrome and diabetes mellitus: clinical evidence for direct positive influence of antidiabetic therapy on left ventricular function. Congestive heart failure (Greenwich, Conn.) 20090101
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovascular diabetology 20090101
Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. Bratislavske lekarske listy 20090101
Drugs associated with more suicidal ideations are also associated with more suicide attempts. PloS one 20090101
Diabetic nephropathy. Diabetology & metabolic syndrome 20090101
Post-transplant diabetes mellitus. Diabetology & metabolic syndrome 20090101
Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. BMJ (Clinical research ed.) 20090101
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ (Clinical research ed.) 20090101
Glinide, but not sulfonylurea, can evoke insulin exocytosis by repetitive stimulation: imaging analysis of insulin exocytosis by secretagogue-induced repetitive stimulations. Experimental diabetes research 20090101
Effect of Ramadan fasting on anthropometric parameters and food consumption in 276 type 2 diabetic obese women. International journal of diabetes in developing countries 20090101
Repaglinide induced acute hepototoxicity. JNMA; journal of the Nepal Medical Association 20090101
Role of potassium channels in stretch-promoted atrial natriuretic factor secretion. Journal of the American Society of Hypertension : JASH 20090101
pH-Sensitive Mebeverine Microspheres for Colon Delivery. Indian journal of pharmaceutical sciences 20090101
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective. Diabetes, metabolic syndrome and obesity : targets and therapy 20090101
Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy 20090101
Fixed combination of repaglinide and metformin in the management of type 2 diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy 20090101
Analysis of nine drugs and their cytochrome P450-specific probe metabolites from urine by liquid chromatography-tandem mass spectrometry utilizing sub 2 microm particle size column. Journal of chromatography. A 20081226
Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. Diabetes, obesity & metabolism 20081201
The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. British journal of clinical pharmacology 20081201
Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. Vascular health and risk management 20081201
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes. Vascular health and risk management 20081201
Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes care 20081101
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Pharmacogenetics and genomics 20081101
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. Journal of medicinal chemistry 20081009
Weight change in diabetes and glycemic and blood pressure control. Diabetes care 20081001
Reversible binding of antidiabetic drugs, repaglinide and gliclazide, with human serum albumin. Chemical biology & drug design 20081001
International Diabetes Federation guideline for management of postmeal glucose: a review of recommendations. Diabetic medicine : a journal of the British Diabetic Association 20081001
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism. Clinical pharmacology and therapeutics 20081001
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clinical pharmacology and therapeutics 20080901
Application of software design principles and debugging methods to an analgesia prescription reduces risk of severe injury from medical use of opioids. Clinical pharmacology and therapeutics 20080901
Glycemic control in diabetes: a tale of three studies. Diabetes care 20080901
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. The pharmacogenomics journal 20080801
Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties. Bioorganic & medicinal chemistry letters 20080801
Approaches to treatment of type 2 diabetes. Diabetes care 20080801
Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta pharmacologica Sinica 20080801
Novel de novo mutation in sulfonylurea receptor 1 presenting as hyperinsulinism in infancy followed by overt diabetes in early adolescence. Diabetes 20080701
Drugs for type 2 diabetes. Treatment guidelines from the Medical Letter 20080701
Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 20080601
Interaction of Aqueous Extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in Alloxan Induced Diabetic Mice. Evidence-based complementary and alternative medicine : eCAM 20080601
Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. The AAPS journal 20080601
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions. Pharmaceutical research 20080501
Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. European journal of endocrinology 20080501
Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Pharmacotherapy 20080501
Development and validation of a liquid chromatography/tandem mass spectrometry assay for the simultaneous determination of nateglinide, cilostazol and its active metabolite 3,4-dehydro-cilostazol in Wistar rat plasma and its application to pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080401
[Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes]. Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20080401
Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta diabetologica 20080301
Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide. Journal of clinical pharmacology 20080301
Hypoglycaemia in Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 20080301
Spermicidal activity of sulfonylureas and meglitinide analogues: role of intrasperm Ca2+ elevation. The Journal of pharmacy and pharmacology 20080301
Achieving glycosylated hemoglobin targets using the combination of repaglinide and metformin in type 2 diabetes: a reanalysis of earlier data in terms of current targets. Clinical therapeutics 20080301
Postprandial hyperglycemia: are all sulfonylureas created equal? The American journal of cardiology 20080215
Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. European journal of clinical pharmacology 20080201
Ameliorating effects of sulfonylurea drugs on insulin resistance in Otsuka long-evans Tokushima Fatty rats. The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20080201
Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. Diabetes research and clinical practice 20080101
Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. European journal of endocrinology 20080101
Electrochemical determination of the antidiabetic drug repaglinide. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20080101
Radioiodinated naphthylalanine derivatives targeting pancreatic beta cells in normal and nonobese diabetic mice. Experimental diabetes research 20080101
The relationship between type of drug therapy and blood glucose self-monitoring test strips claimed by beneficiaries of the Seniors' Pharmacare Program in Nova Scotia, Canada. BMC health services research 20080101
A comparative study of first-derivative spectrophotometry and column high-performance liquid chromatography applied to the determination of repaglinide in tablets and for dissolution testing. Journal of AOAC International 20080101
Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin : randomized, single-blind, three-period crossover study in healthy subjects. Clinical drug investigation 20080101
Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PloS one 20080101
Diabetes: glycaemic control in type 2. BMJ clinical evidence 20080101
Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. International journal of clinical practice 20071201
A review of nateglinide in the management of patients with type 2 diabetes. Vascular health and risk management 20071201
Optimizing combination treatment in the management of type 2 diabetes. Vascular health and risk management 20071001
A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes. Vascular health and risk management 20071001
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Annals of internal medicine 20070918
Multi-component plasma quantitation of anti-hyperglycemic pharmaceutical compounds using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070901
Testing the bipartite model of the sulfonylurea receptor binding site: binding of A-, B-, and A + B-site ligands. The Journal of pharmacology and experimental therapeutics 20070801
Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. The Journal of clinical investigation 20070801
Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes. Current medical research and opinion 20070801
Rapidly dissolving repaglinide powders produced by the ultra-rapid freezing process. AAPS PharmSciTech 20070720
A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. Diabetic medicine : a journal of the British Diabetic Association 20070701
Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. Diabetes, obesity & metabolism 20070701
Development of a RP-HPLC method for screening potentially counterfeit anti-diabetic drugs. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20070615
Pioglitazone and sulfonylureas: effectively treating type 2 diabetes. International journal of clinical practice. Supplement 20070601
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes, obesity & metabolism 20070501
Meglitinide analogues for type 2 diabetes mellitus. The Cochrane database of systematic reviews 20070418
Method development and validation of repaglinide in human plasma by HPLC and its application in pharmacokinetic studies. Journal of pharmaceutical and biomedical analysis 20070411
New oral agents for type 2 diabetes. Clinical medicine (London, England) 20070401
Porous carrier based floating granular delivery system of repaglinide. Drug development and industrial pharmacy 20070401
[Chronic kidney disease and antidiabetic treatment]. Revue medicale suisse 20070307
A comparison of glycemic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes research and clinical practice 20070201
Glibenclamide attenuates the antiarrhythmic effect of endotoxin with a mechanism not involving K(ATP) channels. Vascular pharmacology 20070201
Effect of a hypoglycemic agent on ischemic preconditioning in patients with type 2 diabetes and stable angina pectoris. Coronary artery disease 20070201
Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. Diabetic medicine : a journal of the British Diabetic Association 20070201
Use of repaglinide on a pregnant woman during embryogenesis. Diabetes, obesity & metabolism 20070101
Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clinical pharmacokinetics 20070101
Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. Health and quality of life outcomes 20070101
Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. Cardiovascular diabetology 20070101
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101
Rapid identification of P-glycoprotein substrates and inhibitors. Drug metabolism and disposition: the biological fate of chemicals 20061201
Preprandial repaglinide decreases exogenous insulin requirements and HbA1c levels in type 2 diabetic patients taking intensive insulin treatment. Acta diabetologica 20061201
Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. British journal of clinical pharmacology 20061101
Simultaneous estimation of six anti-diabetic drugs--glibenclamide, gliclazide, glipizide, pioglitazone, repaglinide and rosiglitazone: development of a novel HPLC method for use in the analysis of pharmaceutical formulations and its application to human plasma assay. Biomedical chromatography : BMC 20061001
Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women. Diabetes care 20061001
Selectivity of repaglinide and glibenclamide for the pancreatic over the cardiovascular K(ATP) channels. Diabetologia 20060901
Cyclosporine A increases plasma concentrations and effects of repaglinide. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901
Pharmacological interaction between cyclosporine a and repaglinide. Is it clinically relevant? American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060901
Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial. Diabetes care 20060801
Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20060801
Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 20060725
A novel calcium silicate based microspheres of repaglinide: in vivo investigations. Journal of controlled release : official journal of the Controlled Release Society 20060628
Ionization, lipophilicity and solubility properties of repaglinide. Journal of pharmaceutical and biomedical analysis 20060607
Determination of clopidogrel metabolite (SR26334) in human plasma by LC-MS. Journal of pharmaceutical and biomedical analysis 20060503
Microsphere-based protease assays and screening application for lethal factor and factor Xa. Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501
Peroxisome proliferator-activated receptor gamma agonists in renal disease. European journal of endocrinology 20060501
Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. Acta diabetologica 20060501
Transporters as a determinant of drug clearance and tissue distribution. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060401
Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20060401
Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes & metabolism 20060401
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. European journal of clinical pharmacology 20060301
Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. International journal of clinical practice 20060301
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clinical pharmacology and therapeutics 20060301
An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. The Medical journal of Malaysia 20060301
Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabetic medicine : a journal of the British Diabetic Association 20060201
Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug metabolism and disposition: the biological fate of chemicals 20060101
The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide. British journal of clinical pharmacology 20060101
Pioglitazone: a review of its use in type 2 diabetes mellitus. Drugs 20060101
Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Current medicinal chemistry 20060101
Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovascular diabetology 20060101
Treatment of impaired glucose tolerance with acarbose and its effect on intima-media thickness: a substudy of the STOP-NIDDM trial (study to prevent non-insulin-dependent diabetes mellitus). Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101
Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/metabolism research and reviews 20060101
Development and validation of a new high-performance liquid chromatography method for the determination of gliclazide and repaglinide in pharmaceutical formulations. Journal of AOAC International 20060101
Spotlight on pioglitazone in type 2 diabetes mellitus. Treatments in endocrinology 20060101
Patient-reported outcomes in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health and quality of life outcomes 20060101
Type 2 diabetes mellitus: a review of pharmacological treatment. Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria 20060101
Basic Management of Diabetes Mellitus: Practical guidelines. The Libyan journal of medicine 20060101
Modification of cardiac oxidative stress in alloxan-induced diabetic rabbits with repaglinide treatment. Life sciences 20051205
Oral agents in managing diabetes mellitus in children and adolescents. Pediatric clinics of North America 20051201
[Synthesis and insulinotropic activity of 2-benzylidenesuccinic acid derivatives]. Yao xue xue bao = Acta pharmaceutica Sinica 20051201
Calcium silicate based microspheres of repaglinide for gastroretentive floating drug delivery: preparation and in vitro characterization. Journal of controlled release : official journal of the Controlled Release Society 20051003
Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association 20051001
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin. Basic & clinical pharmacology & toxicology 20051001
Cyclosporine markedly raises the plasma concentrations of repaglinide. Clinical pharmacology and therapeutics 20051001
[Recent oral antidiabetic therapy]. Revue medicale de Bruxelles 20050901
Antioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animals. Pharmacological research 20050801
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. British journal of clinical pharmacology 20050801
Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin. Diabetes care 20050701
Mild, reversible pancytopenia induced by rosiglitazone. Diabetes care 20050601
Oxidative stress in kidney and liver of alloxan-induced diabetic rabbits: effect of repaglinide. Acta diabetologica 20050601
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical pharmacology and therapeutics 20050601
Prediction of genotoxicity of chemical compounds by statistical learning methods. Chemical research in toxicology 20050601
Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes & metabolism 20050601
Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients. Diabetes care 20050501
Effects of repaglinide on oxidative stress in tissues of diabetic rabbits. Diabetes research and clinical practice 20050501
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharmaceutical research 20050401
Cholestatic hepatitis associated with repaglinide. Diabetes care 20050301
[Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition 20050301
Oral antihyperglycemic agents and renal disease: new agents, new concepts. Journal of the American Society of Nephrology : JASN 20050301
Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes care 20050201
Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. British journal of pharmacology 20050201
Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. The Israel Medical Association journal : IMAJ 20050201
Sulfonylurea induced beta-cell apoptosis in cultured human islets. The Journal of clinical endocrinology and metabolism 20050101
Effect of repaglinide and gliclazide on postprandial control of endogenous glucose production. Metabolism: clinical and experimental 20050101
Examination of 209 drugs for inhibition of cytochrome P450 2C8. Journal of clinical pharmacology 20050101
Islet adaptation to insulin resistance: mechanisms and implications for intervention. Diabetes, obesity & metabolism 20050101
Cardiovascular risk factors associated with insulin resistance: effects of oral antidiabetic agents. American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101
Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug safety 20050101
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clinical pharmacokinetics 20050101
Postprandial glucose regulation: new data and new implications. Clinical therapeutics 20050101
Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetes. Core evidence 20050101
The impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardium. Diabetes 20041201
Accuracy of continuous nocturnal glucose screening after 48 and 72 hours in type 2 diabetes patients on combined oral and insulin therapy. Diabetes & metabolism 20041201
Acute hepatotoxicity caused by repaglinide. Annals of internal medicine 20041116
Detection of anti-diabetics in equine plasma and urine by liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20041105
Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. Diabetic medicine : a journal of the British Diabetic Association 20041101
Synthesis and in vitro evaluation of (S)-2-([11C]methoxy)-4-[3-methyl-1-(2-piperidine-1-yl-phenyl)-butyl-carbamoyl]-benzoic acid ([11C]methoxy-repaglinide): a potential beta-cell imaging agent. Bioorganic & medicinal chemistry letters 20041018
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide. British journal of clinical pharmacology 20041001
The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabetic medicine : a journal of the British Diabetic Association 20041001
Taurine block of cloned ATP-sensitive K+ channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. Biochemical pharmacology 20040901
Beta-cell insulin secretory response to oral hypoglycemic agents is blunted in humans in vivo during moderate hypoglycemia. The Journal of clinical endocrinology and metabolism 20040901
Studies on the glycemic and lipidemic effect of monopril and losartan in normal and diabetic rats. Pharmacological research 20040801
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes. Current medical research and opinion 20040801
Treating type 2 diabetes. When diet and exercise aren't enough, a broad range of medications can help control our blood sugar. Health news (Waltham, Mass.) 20040801
Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 20040713
Synthesis and evaluation of (S)-2-(2-[18F]fluoroethoxy)-4-([3-methyl-1-(2-piperidin-1-yl-phenyl)-butyl-carbamoyl]-methyl)-benzoic acid ([18F]repaglinide): a promising radioligand for quantification of pancreatic beta-cell mass with positron emission tomography (PET). Nuclear medicine and biology 20040701
Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040701
Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes care 20040601
Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes, nutrition & metabolism 20040601
Evidence for hypothalamic K+(ATP) channels in the modulation of glucose homeostasis. European journal of pharmacology 20040510
The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocrine research 20040501
Inhibitors of ATP-sensitive potassium channels in guinea pig isolated ischemic hearts. Naunyn-Schmiedeberg's archives of pharmacology 20040401
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. British journal of clinical pharmacology 20040401
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide. European journal of clinical pharmacology 20040401
Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes. Diabetes research and clinical practice 20040401
Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabetic medicine : a journal of the British Diabetic Association 20040401
Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Archives of internal medicine 20040308
The effects of oral anti-hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes, obesity & metabolism 20040301
Treatment of type 2 diabetes with a combination regimen of repaglinide plus pioglitazone. Diabetes research and clinical practice 20040201
Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes & metabolism 20040201
The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. The Journal of clinical endocrinology and metabolism 20040101
Clinical pharmacokinetics of nateglinide: a rapidly-absorbed, short-acting insulinotropic agent. Clinical pharmacokinetics 20040101
Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. PharmacoEconomics 20040101
Mitiglinide: KAD 1229, S 21403. Drugs in R&D 20040101
Compared to glibenclamide, repaglinide treatment results in a more rapid fall in glucose level and beta-cell secretion after glucose stimulation. Diabetes/metabolism research and reviews 20040101
Interactions between grapefruit juice and cardiovascular drugs. American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101
Continuous glucose monitoring: physiologic and pathophysiologic significance. Romanian journal of internal medicine = Revue roumaine de medecine interne 20040101
The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta medica Indonesiana 20040101
[Continuation 50. Type 2 diabetes: possibilities and limitations of pharmacological therapy]. MMW Fortschritte der Medizin 20031218
Glimepiride and serum adiponectin level in type 2 diabetic subjects: response to Nagasaka et al. Diabetes care 20031201
Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al. Diabetes care 20031201
Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection. Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20031201
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. British journal of cancer 20031117
[Type 2 diabetes mellitus pathogenesis: new therapeutic managements?]. La Revue de medecine interne 20031101
Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabetic medicine : a journal of the British Diabetic Association 20031101
Neuronal calcium sensor proteins are direct targets of the insulinotropic agent repaglinide. The Biochemical journal 20031001
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical pharmacology and therapeutics 20031001
Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20031001
CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. British journal of clinical pharmacology 20030901
Lack of effect of acute repaglinide administration on postprandial lipaemia in patients with type 2 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030901
Cardiovascular risk in type 2 diabetics and pharmacological regulation of mealtime glucose excursions. Diabetes & metabolism 20030901
Impurity profile study of repaglinide. Journal of pharmaceutical and biomedical analysis 20030714
Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes care 20030701
[symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes? Drug and therapeutics bulletin 20030701
A comparison of costs for four oral antidiabetic regimens within a managed care population. Managed care interface 20030701
Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes research and clinical practice 20030601
The effect of prandial glucose regulation with repaglinide on treatment satisfaction, wellbeing and health status in patients with pharmacotherapy naïve Type 2 diabetes: a placebo-controlled, multicentre study. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 20030601
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. Journal of clinical pharmacology 20030601
[Meglitinide analogs: new insulinotropic agents for the treatment of non-insulin dependent diabetes]. Revue medicale de Bruxelles 20030601
[Differences between oral antidiabetics]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke 20030320
Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes care 20030301
Metformin-induced hemolytic anemia in a patient with glucose-6- phosphate dehydrogenase deficiency. Diabetes care 20030301
Pharmacologic restoration of the early insulin response in pre-diabetic monkeys controls mealtime glucose excursions without peripheral hyperinsulinaemia. Diabetologia 20030301
The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type II diabetes mellitus. Diabetologia 20030301
The mechanisms underlying the unique pharmacodynamics of nateglinide. Diabetologia 20030301
Rationale and options for combination therapy in the treatment of Type 2 diabetes. Diabetologia 20030301
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. Diabetologia 20030301
Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clinical therapeutics 20030201
The effect of repaglinide on insulin secretion and oxidative stress in type 2 diabetic patients. Diabetes research and clinical practice 20030101
Pharmacokinetics of repaglinide in healthy caucasian and Japanese subjects. Journal of clinical pharmacology 20030101
Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. Journal of diabetes and its complications 20030101
Economic model of first-line drug strategies to achieve recommended glycaemic control in newly diagnosed type 2 diabetes mellitus. PharmacoEconomics 20030101
[Drug safety. Notes regarding drug surveillance]. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria 20030101
Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treatments in endocrinology 20030101
Effects of S 21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. European journal of pharmacology 20021205
No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers. Journal of clinical pharmacology 20021201
Sulfonylurea stimulation of insulin secretion. Diabetes 20021201
Early changes in beta-cell function and insulin pulsatility as predictors for type 2 diabetes. Diabetes, nutrition & metabolism 20021201
Repaglinide at a cellular level. Diabetes, nutrition & metabolism 20021201
Early-phase prandial insulin secretion: its role in the pathogenesis of type 2 diabetes mellitus and its modulation by repaglinide. Diabetes, nutrition & metabolism 20021201
The impact of prandial glucose regulation in practice. Diabetes, nutrition & metabolism 20021201
Repaglinide in combination therapy. Diabetes, nutrition & metabolism 20021201
High-frequency insulin pulsatility and type 2 diabetes: from physiology and pathophysiology to clinical pharmacology. Diabetes & metabolism 20021201
Hypoglycemia probably due to accidental intake of repaglinide. Chang Gung medical journal 20021101
Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes research and clinical practice 20021001
Repaglinide versus metformin in combination with bedtime NPH insulin in patients with type 2 diabetes established on insulin/metformin combination therapy. Diabetes care 20021001
Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 20020901
[Structures and mechanisms for non SU insulin secretagogues]. Nihon rinsho. Japanese journal of clinical medicine 20020901
[Repaglinide (NN-623)]. Nihon rinsho. Japanese journal of clinical medicine 20020901
A novel simple method for the investigation of drug binding to the K(ATP) channel sulfonylurea receptor. Analytical biochemistry 20020815
Comparison of the effects of three insulinotropic drugs on plasma insulin levels after a standard meal. Diabetes care 20020801
Response to Schmitz. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes care 20020801
[Differential type 2 diabetes therapy based on pathophysiological aspects]. Therapeutische Umschau. Revue therapeutique 20020801
Nateglinide, but not repaglinide, stimulates growth hormone release in rat pituitary cells by inhibition of K channels and stimulation of cyclic AMP-dependent exocytosis. European journal of endocrinology 20020701
Interaction of nateglinide with K(ATP) channel in beta-cells underlies its unique insulinotropic action. European journal of pharmacology 20020503
[Glinides and glitazones in diabetes treatment. Are they really effective?]. MMW Fortschritte der Medizin 20020502
Current oral agents for type 2 diabetes. Many options, but which to choose when? Postgraduate medicine 20020501
Insulinotropic meglitinide analogues. Lancet (London, England) 20020406
Subclinical type 1 diabetes. Journal of the Royal Society of Medicine 20020401
[Postprandial hyperglycemia. II. Pharmacological approaches]. Revue medicale de Liege 20020401
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutrition, metabolism, and cardiovascular diseases : NMCD 20020401
Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Diabetes care 20020201
Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 20020116
Type 2 diabetes management. British journal of community nursing 20020101
Modeling the pharmacokinetics and pharmacodynamics of a unique oral hypoglycemic agent using neural networks. Pharmaceutical research 20020101
The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. Journal of diabetes and its complications 20020101
Type 2 diabetes management: a comprehensive clinical review of oral medications. Comprehensive therapy 20020101
Gateways to clinical trials. Methods and findings in experimental and clinical pharmacology 20020101
Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clinical pharmacokinetics 20020101
Study of the insulinotropic effect of the novel antihyperglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. Arzneimittel-Forschung 20020101
Insulin secretagogues. Current medical research and opinion 20020101
Preventing the progressive nature of type 2 diabetes. Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners 20020101
Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clinical pharmacokinetics 20020101
Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. Journal of postgraduate medicine 20020101
Postprandial hyperglycemia in patients with type 2 diabetes mellitus. Treatments in endocrinology 20020101
Insulinotropic meglitinide analogues. Lancet (London, England) 20011117
The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive K+ channels and insulin secretion: comparison with the sulfonylureas and nateglinide. European journal of pharmacology 20011109
Nateglinide therapy for type 2 diabetes mellitus. The Annals of pharmacotherapy 20011101
[Therapy of type 2 diabetes. Avoiding postprandial blood glucose peaks!]. MMW Fortschritte der Medizin 20011004
Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes care 20011001
Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes care 20011001
Effect of insulinotropic agent nateglinide on Kv and Ca(2+) channels in pancreatic beta-cell. European journal of pharmacology 20010914
Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Current pharmaceutical design 20010901
Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes. Diabetes research and clinical practice 20010901
[New drugs]. Revue medicale de Bruxelles 20010901
[News in oral antidiabetic therapy]. Vnitrni lekarstvi 20010901
[Repaglinide, potentially a therapeutic improvement for diabetes mellitus type 2]. Nederlands tijdschrift voor geneeskunde 20010811
Utilization of oral hypoglycemic agents in a drug-insured U.S. population. Diabetes care 20010801
A new era in type 2 diabetes mellitus treatment? The American journal of medicine 20010701
The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide. Clinical pharmacology and therapeutics 20010701
[Objectives and therapeutic strategy in type 2 diabetes mellitus]. Anales de medicina interna (Madrid, Spain : 1984) 20010701
Effect of repaglinide on cloned beta cell, cardiac and smooth muscle types of ATP-sensitive potassium channels. Diabetologia 20010601
[Pharma-clinics. Medication of the month. Repaglinide (NovoNorm)]. Revue medicale de Liege 20010601
[Repaglinide]. Deutsche medizinische Wochenschrift (1946) 20010511
Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. European journal of clinical pharmacology 20010501
Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study. Diabetic medicine : a journal of the British Diabetic Association 20010501
Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions. Diabetes, obesity & metabolism 20010401
[Large general practice study with repaglinide. Fewer 'anxiety eating' in diabetic patients]. MMW Fortschritte der Medizin 20010308
Repaglinide-induced factitious hypoglycemia. The Journal of clinical endocrinology and metabolism 20010201
Repaglinide and diabetes: new preparation. No better than glucose-lowering sulphonamides. Prescrire international 20010201
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia. The Journal of the Association of Physicians of India 20010125
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes. The Journal of the Association of Physicians of India 20010125
Combination therapy in type 2 diabetes: the role of repaglinide. The Journal of the Association of Physicians of India 20010125
Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Diabetes care 20010101
Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes care 20010101
Honing type 2 diabetes treatment. Health news (Waltham, Mass.) 20010101
Oral hypoglycemic agents: insulin secretagogues, alpha-glucosidase inhibitors and insulin sensitizers. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101
Repaglinide: a review of its therapeutic use in type 2 diabetes mellitus. Drugs 20010101
[New molecules]. Journal de pharmacie de Belgique 20010101
Patient perceptions of prandial oral therapy for type 2 diabetes. The Diabetes educator 20010101
Glucose-dependent and glucose-sensitizing insulinotropic effect of nateglinide: comparison to sulfonylureas and repaglinide. International journal of experimental diabetes research 20010101
Effectiveness of nateglinide on in vitro insulin secretion from rat pancreatic islets desensitized to sulfonylureas. International journal of experimental diabetes research 20010101
Pharmacology and clinical experience with repaglinide. Expert opinion on investigational drugs 20000401

© 2019 Angene International Limited. All rights Reserved.